Eli Lilly and Company (LLY) on Thursday reported positive results from its Phase 3 ACHIEVE-3 trial evaluating orforglipron in adults with type 2 diabetes inadequately controlled on metformin, compared with oral semaglutide.
In the 52-week study, orforglipron outperformed semaglutide across the primary and all key secondary endpoints, showing significantly greater reductions in A1C and body weight. Specifically, orforglipron lowered A1C by 2.2%, compared with a 1.4% reduction for semaglutide.
The results were published today in The Lancet.
Lilly has submitted orforglipron to regulators in over 40 countries and plans to submit for U.S. approval for type 2 diabetes later this year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.